Results 11 to 20 of about 3,797 (192)

Simeprevir for the treatment of hepatitis C virus infection

Pharmacogenomics and Personalized Medicine, 2014
Laure Izquierdo,1 François Helle,1 Catherine François,1,2 Sandrine Castelain,1,2 Gilles Duverlie,1,2 Etienne Brochot1,2 1Virology Research Unit, Jules Verne University of Picardie, 2Department of Virology, Amiens University Hospital, Amiens,
Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E   +5 more
doaj   +1 more source

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir

Therapeutics and Clinical Risk Management, 2014
Tatsuo Kanda, Shingo Nakamoto, Shuang Wu, Osamu Yokosuka Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan Abstract: Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and ...
Kanda T, Nakamoto S, Wu S, Yokosuka O
doaj   +1 more source

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

BMC Infectious Diseases, 2017
Background This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infected treatment ...
Edward J. Gane, Edwin DeJesus, Ewa Janczewska, Jacob George, Moises Diago, Mariliza Hendrique Da Silva, Henk Reesink, Igor Nikitin, Holger Hinrichsen, Stefan Bourgeois, Peter Ferenci, Umesh Shukla, Ronald Kalmeijer, Oliver Lenz, Bart Fevery, Chris Corbett, Maria Beumont, Wolfgang Jessner   +17 more
doaj   +2 more sources

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. [PDF]

PLoS ONE, 2017
BackgroundHCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection.
Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Faisal Sanai, Ceyhun Bicer, Oliver Lenz, Gino Van Dooren, Catherine Nalpas, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti   +14 more
doaj   +2 more sources

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort [PDF]

BMC Infectious Diseases, 2019
Background Although real-life results of sofosbuvir/simeprevir have been extensively reported from the United States, data from other geographical areas are limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients were given the new
Anne Laurain, Sophie Metivier, Georges Haour, Dominique Larrey, Céline Dorival, Christophe Hezode, Fabien Zoulim, Patrick Marcellin, Marc Bourliere, Jean-Pierre Zarski, Dominique Thabut, Laurent Alric, Nathalie Ganne-Carrie, Paul Cales, Jean-Pierre Bronowicki, Ghassan Riachi, Claire Geist, Xavier Causse, Armand Abergel, Olivier Chazouilleres, Philippe Mathurin, Dominique Guyader, Didier Samuel, Albert Tran, Véronique Loustaud-Ratti, Ventzislava Petrov-Sanchez, Alpha Diallo, Clovis Luzivika-Nzinga, Hélène Fontaine, Fabrice Carrat, Stanislas Pol, on behalf of the ANRS/AFEF HEPATHER study group   +31 more
doaj   +2 more sources

Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection

Annals of Hepatology, 2018
Interferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available ...
Mitsuyoshi Suzuki, Kei Minowa, Hitoshi Tajiri   +2 more
doaj   +2 more sources

An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory Circumstances. [PDF]

Pharmacol Res Perspect
ABSTRACT The approval requirements in new regions that do not require domestic clinical data and the clinical data evaluation of multi‐regional clinical trials (MRCTs) and foreign clinical trials (FCTs) in the Japanese approval review processes for antimicrobial medicines were explored.
Shimazawa R, Ikeda M.
europepmc   +2 more sources

Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment

Annals of Hepatology, 2017
The addition of the new protease inhibitors (PIs) to peg-interferon (IFN) and ribavirin (RBV), approved for chronic hepatitis C, has clearly improved sustained virological response (SVR) rates although several adverse events have been reported with this ...
Alicia Senín, Teresa Broquetas, Sabela Lens, Nuria Cañete, María-Carlota Londoño, Mariana Ferraro, Xavier Forns, Antonio Salar, Jose A. Carrión   +8 more
doaj   +3 more sources

Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir [PDF]

, 2021
International audienceThe outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global threat to human health. Using a multidisciplinary approach, we identified and validated the
Junzhe Huang, Vincent C. T. Mok, Wang, Kaidao, Jean-Claude Guillemot, Xu He, Bowen Ma, Mok, Vincent, Chan, Michael Chi Wai, Po-Huang Liang, Peter Man-Hin Cheung, Bruno Canard, Huang, Junzhe, Chen, Yu Wai, Ng, Ka-Chun, Aik, Wei Shen, Ng, Wai-Lung, Li, Zhongqi, Eydoux, Cécilia, Canard, Bruno, Meng-Hsuan Lee, Mok, Chris Ka Pun, He, Xu, Khan, Khadija Shahed, David S. C. Hui, Ho Sing Lo, Francis K. L. Chan, Ko, Ho, Ho Ko, Khadija Shahed Khan, Lai, Hei-Ming, Cecilia Eydoux, Lee, Meng-Hsuan, Hayley Hei-Yin Cheung, Liang, Po-Huang, Ma, Bowen, Hui, Kenrie Pui Yan, Kaidao Wang, Wu, Kuen-Phon, Barbara Selisko, Simranjeet Kaur, Zhongqi Li, Kam-Bo Wong, Donghyuk Shin, Chris Ka Pun Mok, Ivan Dikic, Yu Wai Chen, John Chi Wang Ho, Wei Shen Aik, Chan, Anthony, Michael Chi Wai Chan, Zhong Zuo, Ka-Chun Ng, Hui, David, Ho, John Chi Wang, Lo, Ho Sing, Kuen-Phon Wu, Kenrie Pui Yan Hui, Cheung, Peter Man-Hin, Cheung, Hayley Hei-Yin, Chan, Francis, Dikic, Ivan, Wong, Kam-Bo, Wai-Lung Ng, Kaur, Simranjeet, Anthony K. N. Chan, Hei-Ming Lai, Guillemot, Jean-Claude, Shin, Donghyuk, Zuo, Zhong   +68 more
core   +2 more sources

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target-Bound. [PDF]

Chemistry
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Wieske LHE, Bu G, Erdélyi M, Kihlberg J, Gonen T, Danelius ER.   +5 more
europepmc   +2 more sources